These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 32699984)

  • 1. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.
    Tiribelli M; Eskazan AE
    Oncol Ther; 2019 Dec; 7(2):95-100. PubMed ID: 32699984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2024 Aug; ():. PubMed ID: 39093014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors.
    Chopade P; Akard LP
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):710-723. PubMed ID: 30093283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.
    Kronick O; Chen X; Mehra N; Varmeziar A; Fisher R; Kartchner D; Kota V; Mitchell CS
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
    Ono T
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.
    Eskazan AE; Keskin D
    Ther Adv Hematol; 2017 Sep; 8(9):237-243. PubMed ID: 29051802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
    Haznedaroglu IC
    Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
    Ai J; Tiu RV
    Ther Adv Hematol; 2014 Aug; 5(4):107-20. PubMed ID: 25360237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia.
    Amarante-Mendes GP; Rana A; Datoguia TS; Hamerschlak N; Brumatti G
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
    Singh AP; Umbarkar P; Tousif S; Lal H
    Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.